3/13
04:28 pm
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $11.00. They now have an "overweight" rating on the stock.
Medium
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $11.00. They now have an "overweight" rating on the stock.
3/12
08:00 am
sldb
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Low
Report
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
3/10
08:03 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at HC Wainwright from $16.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at HC Wainwright from $16.00 to $20.00. They now have a "buy" rating on the stock.
3/7
06:21 pm
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $16.00 price target on the stock.
Medium
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $16.00 price target on the stock.
3/6
04:22 pm
sldb
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
3/6
04:16 pm
sldb
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Low
Report
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
3/5
09:02 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Solid Biosciences to Participate at Upcoming Investor Conferences [Yahoo! Finance]
3/5
08:00 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences
Medium
Report
Solid Biosciences to Participate at Upcoming Investor Conferences
3/4
04:07 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/19
07:07 pm
sldb
Solid Biosciences' stock soars on early success in DMD gene therapy trial [Yahoo! Finance]
Medium
Report
Solid Biosciences' stock soars on early success in DMD gene therapy trial [Yahoo! Finance]
2/19
08:00 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at Chardan Capital from $15.00 to $16.00. They now have a "buy" rating on the stock.
High
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at Chardan Capital from $15.00 to $16.00. They now have a "buy" rating on the stock.
2/4
08:00 am
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/21
10:01 am
sldb
Solid Biosciences receives FDA fast track designation for SGT-212 [Seeking Alpha]
Medium
Report
Solid Biosciences receives FDA fast track designation for SGT-212 [Seeking Alpha]
1/21
09:36 am
sldb
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia [Yahoo! Finance]
Medium
Report
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia [Yahoo! Finance]
1/21
08:30 am
sldb
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Medium
Report
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
1/15
04:05 pm
sldb
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
Medium
Report
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
1/10
12:47 pm
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/8
04:05 pm
sldb
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
1/8
08:00 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $16.00 price target on the stock.
High
Report
Solid Biosciences Inc. (NASDAQ: SLDB) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $16.00 price target on the stock.
1/7
04:15 pm
sldb
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Low
Report
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
1/6
08:00 am
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)